Novartis | NVS - Cost Of Sales


Novartis reported $3.54B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Bausch Health Companies USD 979M 55M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
J&J USD 8.07B 103M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
Sanofi EUR 3.76B 344M Dec/2025
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Zoetis USD 672M 71M Mar/2026